IN2015DN03936A - - Google Patents

Info

Publication number
IN2015DN03936A
IN2015DN03936A IN3936DEN2015A IN2015DN03936A IN 2015DN03936 A IN2015DN03936 A IN 2015DN03936A IN 3936DEN2015 A IN3936DEN2015 A IN 3936DEN2015A IN 2015DN03936 A IN2015DN03936 A IN 2015DN03936A
Authority
IN
India
Prior art keywords
plgas
pharmaceutically
acceptable salt
active ingredient
sustained release
Prior art date
Application number
Other languages
English (en)
Inventor
Holger Petersen
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN03936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN03936A publication Critical patent/IN2015DN03936A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IN3936DEN2015 2005-12-22 2006-12-20 IN2015DN03936A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
EP06119086 2006-08-17
PCT/EP2006/012313 WO2007071395A1 (en) 2005-12-22 2006-12-20 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Publications (1)

Publication Number Publication Date
IN2015DN03936A true IN2015DN03936A (de) 2015-10-02

Family

ID=37772904

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3936DEN2015 IN2015DN03936A (de) 2005-12-22 2006-12-20

Country Status (22)

Country Link
US (6) US20090004283A1 (de)
EP (3) EP1968549B1 (de)
JP (4) JP2009520727A (de)
KR (5) KR101245919B1 (de)
CN (1) CN103251929A (de)
AR (1) AR058591A1 (de)
AU (1) AU2006328950B2 (de)
BR (2) BR122019027412B8 (de)
CA (1) CA2631811C (de)
CL (1) CL2018003398A1 (de)
EC (1) ECSP088560A (de)
ES (2) ES2755032T3 (de)
IL (1) IL191842A0 (de)
IN (1) IN2015DN03936A (de)
MA (1) MA30064B1 (de)
NO (1) NO20082988L (de)
PE (1) PE20071139A1 (de)
PL (2) PL2359809T3 (de)
PT (2) PT1968549E (de)
RU (1) RU2464972C2 (de)
TW (2) TWI469788B (de)
WO (1) WO2007071395A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
PT2247282E (pt) * 2008-01-30 2014-11-11 Novartis Ag Formulação de libertação controlada compreendendo octreotido e três polímeros lineares de polilactido-coglicolido
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
MX348705B (es) 2008-09-17 2017-06-26 Chiasma Inc Composiciones farmacéuticas y métodos de administración relacionados.
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
WO2010085609A2 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
EP2595604B1 (de) * 2010-07-21 2016-03-30 Allergan, Inc. Verfahren zur steuerung der anfänglichen wirkstofffreisetzung von sirna aus retard-implantaten
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
KR101539313B1 (ko) 2011-04-25 2015-07-24 산동 루예 파마슈티칼 컴파니 리미티드 리스페리돈의 서방성 미소구체 조성물
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
EP3318174A4 (de) * 2015-06-26 2019-04-10 Olympus Corporation Stromversorgungssystem für ein endoskop
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
CN114174385B (zh) * 2020-05-08 2023-03-14 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂
US11285109B2 (en) 2020-05-08 2022-03-29 M. Technique Co., Ltd. Microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same
JP6792900B1 (ja) * 2020-05-08 2020-12-02 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE19375086I2 (de) 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
DE69833375D1 (de) * 1997-06-04 2006-04-13 Debio Rech Pharma Sa Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
ES2292655T3 (es) * 2002-03-15 2008-03-16 Alrise Biosystems Gmbh Microparticulas y procedimiento para su preparacion.
MXPA05004927A (es) * 2002-11-06 2005-09-08 Alza Corp Formulaciones de deposito de liberacion controlada.
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
BRPI0412211A (pt) * 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
KR101231856B1 (ko) * 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물

Also Published As

Publication number Publication date
CA2631811C (en) 2017-06-20
ECSP088560A (es) 2008-07-30
JP2016216467A (ja) 2016-12-22
BR122019027412B8 (pt) 2021-07-27
KR101245919B1 (ko) 2013-03-20
EP3603623A1 (de) 2020-02-05
ES2755032T3 (es) 2020-04-21
BR122019027412B1 (pt) 2020-12-01
US20200206306A1 (en) 2020-07-02
US20150037420A1 (en) 2015-02-05
KR20130024988A (ko) 2013-03-08
NO20082988L (no) 2008-08-29
EP1968549A1 (de) 2008-09-17
BRPI0620063A2 (pt) 2011-11-01
AR058591A1 (es) 2008-02-13
EP1968549B1 (de) 2014-05-14
KR20130024986A (ko) 2013-03-08
AU2006328950B2 (en) 2010-07-29
PE20071139A1 (es) 2007-11-16
EP2359809B1 (de) 2019-08-14
WO2007071395A1 (en) 2007-06-28
US20160120935A1 (en) 2016-05-05
PT1968549E (pt) 2014-08-29
EP2359809A1 (de) 2011-08-24
US20220296675A1 (en) 2022-09-22
TWI469788B (zh) 2015-01-21
RU2008129626A (ru) 2010-01-27
US20090004283A1 (en) 2009-01-01
BRPI0620063B1 (pt) 2020-09-08
CL2018003398A1 (es) 2019-04-26
PL1968549T3 (pl) 2014-10-31
CA2631811A1 (en) 2007-06-28
KR20080078000A (ko) 2008-08-26
JP2009520727A (ja) 2009-05-28
PL2359809T3 (pl) 2020-01-31
CN103251929A (zh) 2013-08-21
KR20140133968A (ko) 2014-11-20
JP2015044823A (ja) 2015-03-12
KR20130024987A (ko) 2013-03-08
BRPI0620063A8 (pt) 2018-05-02
US20180140662A1 (en) 2018-05-24
IL191842A0 (en) 2008-12-29
AU2006328950A1 (en) 2007-06-28
TW201424747A (zh) 2014-07-01
JP6239851B2 (ja) 2017-11-29
PT2359809T (pt) 2019-11-04
BRPI0620063B8 (pt) 2021-05-25
KR101458728B1 (ko) 2014-11-05
RU2464972C2 (ru) 2012-10-27
ES2492641T3 (es) 2014-09-10
JP6178772B2 (ja) 2017-08-09
TWI468172B (zh) 2015-01-11
MA30064B1 (fr) 2008-12-01
JP2013177406A (ja) 2013-09-09
TW200803921A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
IN2015DN03936A (de)
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
HK1200092A1 (en) Sustained release formulations
TW200716119A (en) A solid pharmaceutical dosage formulation
MX2007005156A (es) Trehalosa y/o isomaltulosa como excipiente para formulaciones de aroma secas.
MX2010004576A (es) Derivados de pirimidina novedosos.
IL214617A0 (en) Use of controlled release formulations of octreotide
PT2043600T (pt) Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas
MX2009004439A (es) Composicion de ibuprofeno.
DE602006002260D1 (de) Insektenabweisende zusammensetzungen mit verzögerter freisetzung
MX2007003196A (es) Agente y alimento para evitar/mejorar el trastorno digestivo funcional.
TW200621160A (en) Anti-termite agent
TW200942524A (en) Novel aminomethyl benzene derivatives
IL189885A0 (en) Storage-stable sulphonamide formulations
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
MX2007013327A (es) Formulaciones de liberacion prolongada.
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
NO20065791L (no) Asyklovir-formuleringer
PL376130A1 (en) Controlled releases system containing temozolomide
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna
WO2007137216A3 (en) Gastroretentive sustained release formulations
TNSN08271A1 (en) Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
GB0401634D0 (en) A surfactant
GB0327390D0 (en) Pharmaceutical formulations